CNTA 10-Q/A
Centessa Pharmaceuticals plc (CNTA)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered | ||
| * | Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq Stock Market, LLC. |
| Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
| ☒ | Smaller reporting company | |||||
| Emerging growth company | ||||||
EXPLANATORY NOTE
This Amendment No. 1 to the Quarterly Report on Form 10-Q of Centessa Pharmaceuticals plc (the “Company”) for the quarterly period ended June 30, 2024, originally filed with the Securities and Exchange Commission on August 13, 2024 (the “Original Filing”), is being filed solely to correct a typographical error contained in Exhibit 31.2 submitted with the Original Filing, and includes the certifications of the Company’s principal executive officer and principal financial officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002, as required by Rule 13a-14(a) and 15d-14(a) of the Securities Exchange Act of 1934, as amended.
Except as described above, no other changes have been made to the Original Filing, and this Form 10-Q/A does not modify, amend or update in any way any of the financial or other information contained in the Original Filing. This Form 10-Q/A does not reflect events that may have occurred subsequent to the filing date of the Original Filing.
2
Item 6. Exhibits
3
| 101 SCH |
XBRL Taxonomy Extension Schema Document | |
| 101 CAL |
XBRL Taxonomy Extension Calculation Document | |
| 101 DEF |
XBRL Taxonomy Extension Definition Linkbase Document | |
| 101 LAB |
XBRL Taxonomy Extension Labels Linkbase Document | |
| 101 PRE |
XBRL Taxonomy Extension Presentation Link Document | |
| 104 |
Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibit 101.) | |
| (1) | Filed herewith |
| * | This certification will not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent specifically incorporated by reference into such filing. |
| # | Indicates a management contract or any compensatory plan, contract or arrangement. |
4
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| CENTESSA PHARMACEUTICALS PLC | ||||||
| Date: October 18, 2024 | By: | /s/ Saurabh Saha, M.D., Ph.D. | ||||
| Name: Saurabh Saha, M.D., Ph.D. | ||||||
| Title: Chief Executive Officer (Principal Executive Officer) | ||||||
| Date: October 18, 2024 | By: | /s/ John Crowley | ||||
| Name: John Crowley | ||||||
| Title: Chief Financial Officer (Principal Financial Officer) | ||||||
5